MA50045A - Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci - Google Patents
Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ciInfo
- Publication number
- MA50045A MA50045A MA050045A MA50045A MA50045A MA 50045 A MA50045 A MA 50045A MA 050045 A MA050045 A MA 050045A MA 50045 A MA50045 A MA 50045A MA 50045 A MA50045 A MA 50045A
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- methods
- same
- spirocyclic compounds
- spirocyclic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762551714P | 2017-08-29 | 2017-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50045A true MA50045A (fr) | 2020-07-08 |
Family
ID=65526036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050045A MA50045A (fr) | 2017-08-29 | 2018-08-28 | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11161856B2 (fr) |
| EP (1) | EP3675848B1 (fr) |
| JP (1) | JP7177825B2 (fr) |
| KR (1) | KR20200046053A (fr) |
| CN (1) | CN111032034B (fr) |
| AU (1) | AU2018326497A1 (fr) |
| BR (1) | BR112020003946A2 (fr) |
| CA (1) | CA3072926A1 (fr) |
| CL (1) | CL2020000463A1 (fr) |
| CO (1) | CO2020001715A2 (fr) |
| CR (1) | CR20200088A (fr) |
| DO (1) | DOP2020000040A (fr) |
| EA (1) | EA202090296A1 (fr) |
| EC (1) | ECSP20013332A (fr) |
| ES (1) | ES2914363T3 (fr) |
| IL (1) | IL272578A (fr) |
| JO (1) | JOP20200022A1 (fr) |
| MA (1) | MA50045A (fr) |
| MX (1) | MX2020002254A (fr) |
| PE (1) | PE20200665A1 (fr) |
| PH (1) | PH12020500371A1 (fr) |
| RU (1) | RU2020107039A (fr) |
| SG (1) | SG11202000984YA (fr) |
| WO (1) | WO2019046330A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013207252B2 (en) | 2012-01-06 | 2016-06-09 | H.Lundbeck A/S | Carbamate compounds and pharmaceutical compositions thereof |
| ES2861648T3 (es) | 2016-05-12 | 2021-10-06 | Lundbeck La Jolla Research Center Inc | Compuestos de espirociclo y procedimientos de fabricación y uso de los mismos |
| US10899737B2 (en) | 2016-09-19 | 2021-01-26 | Lundbeck La Jolla Research Center, Inc. | Piperazine carbamates and methods of making and using same |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| PE20200664A1 (es) | 2017-08-29 | 2020-06-11 | Lundbeck La Jolla Research Center Inc | Compuestos espirociclicos y sus metodos de preparacion y uso |
| US11161856B2 (en) | 2017-08-29 | 2021-11-02 | H. Lundbeck A/S | Spirocycle compounds and methods of making and using same |
| EP3793547A4 (fr) * | 2018-05-15 | 2021-11-17 | H. Lundbeck A/S | Inhibiteurs de magl |
| CN111505410B (zh) * | 2020-04-02 | 2022-07-29 | 矽力杰半导体技术(杭州)有限公司 | 调光模式检测电路、方法和无调光检测电路及照明系统 |
| EP4139288A1 (fr) | 2020-04-21 | 2023-03-01 | H. Lundbeck A/S | Synthèse d'un inhibiteur de monoacylglycérol lipase |
| UY39516A (es) | 2020-11-13 | 2022-05-31 | H Lundbeck As | Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión |
| US20240174680A1 (en) | 2021-01-29 | 2024-05-30 | Cedilla Therapeutics, Inc. | Cdk2 inhibitors and methods of using the same |
| IL309571A (en) | 2021-06-26 | 2024-02-01 | Cedilla Therapeutics Inc | Cdk2 inhibitors and methods of using the same |
| US20250084065A1 (en) | 2021-12-29 | 2025-03-13 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| CA3250023A1 (fr) | 2022-05-04 | 2023-11-09 | H. Lundbeck A/S | Forme cristalline de 1, 1, 1, 3, 3, 3 -hexafluoropropan-2-yl (s)-1-(pyridazine-3-ylcarbamoyl)-6 azaspiro [2,5] octane-6-carboxylate en tant qu’inhibiteur de la monoacylglycérol lipase |
| EP4665718A1 (fr) | 2023-02-13 | 2025-12-24 | Apogee Pharmaceuticals, Inc. | Petites molécules utilisées en tant qu'inhibiteurs de monoacylglycérol lipase (magl), compositions et utilisation associées |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070523A1 (fr) | 2001-03-07 | 2002-09-12 | Pfizer Products Inc. | Modulateurs de l'activite du recepteur de la chimiokine |
| WO2008023720A1 (fr) * | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | COMPOSÉ D'URÉE OU SEL DUDIT COMPOSé |
| US20110071180A1 (en) | 2008-03-05 | 2011-03-24 | Targacept, Inc. | Sub-type selective amides of diazabicycloalkanes |
| WO2010141817A1 (fr) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Modulateurs d'amide d'acide gras hydrolase de type diamine urée spirocyclique substituée par un groupe hétéroaryle |
| US8653263B2 (en) | 2009-10-23 | 2014-02-18 | Janssen Pharmaceutica | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
| US9108937B2 (en) | 2010-03-04 | 2015-08-18 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mGluR2 |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| EP2444084A1 (fr) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Utilisation d'inhibiteurs de PI3K pour le traitement de l'obésité |
| AU2013207252B2 (en) | 2012-01-06 | 2016-06-09 | H.Lundbeck A/S | Carbamate compounds and pharmaceutical compositions thereof |
| PL2900669T3 (pl) | 2012-09-25 | 2020-01-31 | F. Hoffmann-La Roche Ag | Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek |
| MX2015017961A (es) * | 2013-07-03 | 2016-10-14 | Abide Therapeutics Inc | Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos. |
| CA2979537C (fr) * | 2015-03-18 | 2023-08-29 | Abide Therapeutics, Inc. | Carbamates de piperazine et procedes de preparation et d'utilisation de ceux-ci |
| BR112018000041A2 (pt) | 2015-07-31 | 2018-09-04 | Pfizer Inc. | Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl |
| CN108601769B (zh) * | 2015-11-20 | 2021-09-03 | H.隆德贝克有限公司 | 吡唑化合物及其制备和使用方法 |
| ES2861648T3 (es) | 2016-05-12 | 2021-10-06 | Lundbeck La Jolla Research Center Inc | Compuestos de espirociclo y procedimientos de fabricación y uso de los mismos |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| US11161856B2 (en) | 2017-08-29 | 2021-11-02 | H. Lundbeck A/S | Spirocycle compounds and methods of making and using same |
| PE20200664A1 (es) | 2017-08-29 | 2020-06-11 | Lundbeck La Jolla Research Center Inc | Compuestos espirociclicos y sus metodos de preparacion y uso |
-
2018
- 2018-08-28 US US16/642,713 patent/US11161856B2/en active Active
- 2018-08-28 CR CR20200088A patent/CR20200088A/es unknown
- 2018-08-28 MA MA050045A patent/MA50045A/fr unknown
- 2018-08-28 EP EP18852217.1A patent/EP3675848B1/fr active Active
- 2018-08-28 PE PE2020000297A patent/PE20200665A1/es unknown
- 2018-08-28 BR BR112020003946-2A patent/BR112020003946A2/pt not_active Application Discontinuation
- 2018-08-28 JP JP2020512612A patent/JP7177825B2/ja active Active
- 2018-08-28 SG SG11202000984YA patent/SG11202000984YA/en unknown
- 2018-08-28 ES ES18852217T patent/ES2914363T3/es active Active
- 2018-08-28 CN CN201880054296.1A patent/CN111032034B/zh active Active
- 2018-08-28 CA CA3072926A patent/CA3072926A1/fr not_active Abandoned
- 2018-08-28 WO PCT/US2018/048388 patent/WO2019046330A1/fr not_active Ceased
- 2018-08-28 MX MX2020002254A patent/MX2020002254A/es unknown
- 2018-08-28 KR KR1020207007712A patent/KR20200046053A/ko not_active Withdrawn
- 2018-08-28 JO JOP/2020/0022A patent/JOP20200022A1/ar unknown
- 2018-08-28 AU AU2018326497A patent/AU2018326497A1/en not_active Abandoned
- 2018-08-28 RU RU2020107039A patent/RU2020107039A/ru unknown
- 2018-08-28 EA EA202090296A patent/EA202090296A1/ru unknown
-
2020
- 2020-02-10 IL IL272578A patent/IL272578A/en unknown
- 2020-02-14 CO CONC2020/0001715A patent/CO2020001715A2/es unknown
- 2020-02-21 EC ECSENADI202013332A patent/ECSP20013332A/es unknown
- 2020-02-21 DO DO2020000040A patent/DOP2020000040A/es unknown
- 2020-02-24 PH PH12020500371A patent/PH12020500371A1/en unknown
- 2020-02-25 CL CL2020000463A patent/CL2020000463A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20200022A1 (ar) | 2020-02-02 |
| JP7177825B2 (ja) | 2022-11-24 |
| MX2020002254A (es) | 2020-07-20 |
| CO2020001715A2 (es) | 2020-02-28 |
| BR112020003946A2 (pt) | 2020-09-08 |
| EA202090296A1 (ru) | 2020-08-03 |
| ES2914363T3 (es) | 2022-06-09 |
| DOP2020000040A (es) | 2020-08-31 |
| CN111032034B (zh) | 2023-05-02 |
| RU2020107039A (ru) | 2021-09-30 |
| WO2019046330A1 (fr) | 2019-03-07 |
| PE20200665A1 (es) | 2020-06-11 |
| KR20200046053A (ko) | 2020-05-06 |
| CR20200088A (es) | 2020-04-08 |
| CA3072926A1 (fr) | 2019-03-07 |
| PH12020500371A1 (en) | 2020-12-07 |
| US20210214375A1 (en) | 2021-07-15 |
| EP3675848A4 (fr) | 2021-03-10 |
| IL272578A (en) | 2020-03-31 |
| EP3675848A1 (fr) | 2020-07-08 |
| EP3675848B1 (fr) | 2022-03-23 |
| CL2020000463A1 (es) | 2020-07-10 |
| CN111032034A (zh) | 2020-04-17 |
| ECSP20013332A (es) | 2020-04-22 |
| US11161856B2 (en) | 2021-11-02 |
| SG11202000984YA (en) | 2020-03-30 |
| AU2018326497A1 (en) | 2020-02-20 |
| JP2020532547A (ja) | 2020-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50045A (fr) | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci | |
| MA50041A (fr) | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci | |
| EP3370715A4 (fr) | Composés chimères de ciblage de protéolyse et procédés de préparation et d'utilisation de ceux-ci | |
| EP3455226A4 (fr) | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci | |
| MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
| EP3504213A4 (fr) | Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation | |
| EP3429635A4 (fr) | Composés anti-crispr et leurs procédés d'utilisation | |
| EP3504251A4 (fr) | Polymères réticulés et procédés de préparation et d'utilisation de ceux-ci | |
| EP3645742A4 (fr) | Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation | |
| MA43365A (fr) | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci | |
| EP3778607C0 (fr) | Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation | |
| MA49752A (fr) | Procédés de préparation de composés de pyrrolidine | |
| MA52492A (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| EP3271352A4 (fr) | Carbamates de pipérazine et procédés de préparation et d'utilisation de ceux-ci | |
| EP3504196A4 (fr) | Procédés de préparation d'olaparib | |
| MA48942A (fr) | Composés thérapeutiques, compositions et procédés d'utilisation associés | |
| EP3525764A4 (fr) | Composition orale d'extraits de cannabinoïdes et procédés d'utilisation | |
| MA44611A (fr) | Compositions de composés hydrophobes cristallisés et leurs procédés de préparation et d'utilisation | |
| MA49560A (fr) | Composés cétoniques bicycliques et leurs procédés d'utilisation | |
| EP3429754A4 (fr) | Cartouches de préparation d'échantillons et leurs procédés d'utilisation | |
| MA47167A (fr) | Composés pyrazolopyrimidine et leurs procédés d'utilisation | |
| MA46546A (fr) | Composés thérapeutiques et leurs procédés d'utilisation | |
| EP3468555A4 (fr) | Composés antimicrobiens et leurs procédés d'utilisation | |
| EP3662007A4 (fr) | Agents de matité à base de silice et procédés de préparation et d'utilisation desdits agents |